Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil in Postherpetic Neuralgia
NCT01102101Phase 3Unknown
- Sponsor
- Medical University of Vienna
- Start
- Aug 2010
- Primary completion
- Mar 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remifentanil in postherpetic neuralgia (PHN), sponsored by Medical University of Vienna. Primary endpoint: Stimulus-response function at 7 days. Status: unknown.
02
Drugs
remifentanil
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT01102101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01102101.